{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:27:54Z","timestamp":1772242074207,"version":"3.50.1"},"reference-count":30,"publisher":"Mattioli1885","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,23]]},"abstract":"<jats:p>Background: In Italy, healthcare workers (HCWs) were among the first to receive COVID-19 vaccination. Aim of the present study is to evaluate frequency and severity of adverse events (AEs) following the second dose of BNT162b2 vaccine among HCWs of a large university hospital in Milan, Italy. Methods: One month after having received the second dose of vaccine, HCWs filled-in a form about type, severity, and duration of post-vaccination local and systemic symptoms. We calculated the overall frequency of AEs and used multivariable Poisson regression models (adjusted for sex, age, BMI, smoking, allergy history, previous SARS-CoV-2 infection, anti-hypertensive therapy, and occupation) to calculate risk ratios (RR) and 95% confidence intervals (CI) of AEs according to selected variables. Results: We included 3659 HCWs. Overall, 2801 (76.6%) experienced at least one local event, with pain at injection site being the most frequent (2788, 76.2%). Systemic events were reported by 2080 (56.8%) HCWs, with fatigue (52.3%), muscle pain (42.2%), headache (37.7%), joint pain (31.9%), and fever (26.2%) being the most frequent. Risks of systemic events were associated with female gender (RR=1.14, CI: 1.06-1.23), age (strong decrease with increasing age, p-trend&lt;0.001), allergy history (RR=1.13, CI: 1.05-1.20), and current smoking (RR=0.90, CI: 0.84-0.97). HCWs with previous SARS-CoV-2 infection (even if symptomatic) were not at increased risk. Conclusions: Both local and systemic acute effects after second dose of BNT162b2 vaccine were frequently reported. However, symptoms were mostly light\/mild and of short duration. Thus, our findings support the safety of COVID-19 vaccination in adults in relatively good health.<\/jats:p>","DOI":"10.23749\/mdl.v112i6.12507","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:58:01Z","timestamp":1741161481000},"page":"477-485","source":"Crossref","is-referenced-by-count":1,"title":["Side effects among healthcare workers from a large Milan university hospital after second dose of BNT162b2 mRNA COVID-19 vaccine"],"prefix":"10.23749","volume":"112","author":[{"given":"Elisa","family":"Borroni","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Consonni","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Cugno","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Mangioni","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Bono","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Oggioni","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Uceda Renteria","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Bordini","sequence":"additional","affiliation":[{"name":"Occupational Health Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Domenico","family":"Nava","sequence":"additional","affiliation":[{"name":"Occupational Health Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Letzgus","sequence":"additional","affiliation":[{"name":"Medical Direction, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaminia","family":"Gentiloni Silverj","sequence":"additional","affiliation":[{"name":"Medical Direction, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Castaldi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Rognoni","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, ATS Brianza, Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cavallieri D'Oro","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, ATS Brianza, Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Carugno","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Riboldi","sequence":"additional","affiliation":[{"name":"Occupational Health Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferruccio","family":"Ceriotti","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Cecilia","family":"Pesatori","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","reference":[{"key":"10.23749\/mdl.v112i6.12507_ref1","unstructured":"Johns Hopkins University and Medicine. Coronavirus Resource Center. Published 2021. Accessed October 14, 2021. https:\/\/coronavirus.jhu.edu\/"},{"key":"10.23749\/mdl.v112i6.12507_ref2","doi-asserted-by":"crossref","unstructured":"Haque A, Pant AB. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines. 2020;8(4). doi:10.3390\/vaccines8040739","DOI":"10.3390\/vaccines8040739"},{"key":"10.23749\/mdl.v112i6.12507_ref3","doi-asserted-by":"crossref","unstructured":"Kim KD, Hwang I, Ku KB, Lee S, Kim SJ, Kim C. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. J Microbiol Biotechnol. 2020;30(8):1109-1115. doi:10.4014\/jmb.2006.06006","DOI":"10.4014\/jmb.2006.06006"},{"key":"10.23749\/mdl.v112i6.12507_ref4","doi-asserted-by":"crossref","unstructured":"Ng WH, Liu X, Mahalingam S. Development of vaccines for SARS-CoV-2 [ version 1 ; peer review : 1 approved ]. F1000 Res. 2020;9:1-15.","DOI":"10.12688\/f1000research.25998.1"},{"key":"10.23749\/mdl.v112i6.12507_ref5","unstructured":"WHO. COVID-19 vaccine tracker and landscape. Published 2021. Accessed October 20, 2021. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"10.23749\/mdl.v112i6.12507_ref6","unstructured":"European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. Published 2020. Accessed October 21, 2021. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-first-covid-19-vaccine-authorisation-eu"},{"key":"10.23749\/mdl.v112i6.12507_ref7","unstructured":"U.S. Food and Drug Administration. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. Published 2020. Accessed October 21, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19"},{"key":"10.23749\/mdl.v112i6.12507_ref8","unstructured":"Italian Ministry of Health. Covid-19 vaccine plan. Published 2021. Accessed October 14, 2021. https:\/\/www.salute.gov.it\/portale\/nuovocoronavirus\/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=5452&area=nuovoCoronavirus&menu=vuoto"},{"key":"10.23749\/mdl.v112i6.12507_ref9","doi-asserted-by":"crossref","unstructured":"Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599. doi:10.1038\/s41586-020-2814-7","DOI":"10.1038\/s41586-020-2814-7"},{"key":"10.23749\/mdl.v112i6.12507_ref10","doi-asserted-by":"crossref","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056\/nejmoa2034577","DOI":"10.1056\/NEJMoa2034577"},{"key":"10.23749\/mdl.v112i6.12507_ref11","doi-asserted-by":"crossref","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078-1090. doi:10.1056\/nejmoa2110475","DOI":"10.1056\/NEJMoa2110475"},{"key":"10.23749\/mdl.v112i6.12507_ref12","unstructured":"Il Sole 24 Ore. Vaccini in tempo reale. Published 2021. Accessed October 21, 2021. https:\/\/lab24.ilsole24ore.com\/numeri-vaccini-italia-mondo\/"},{"key":"10.23749\/mdl.v112i6.12507_ref13","unstructured":"Italian Medicines Agency. Rapporto sulla Sorveglianza dei vaccini. Published online 2021. https:\/\/www.aifa.gov.it\/farmacovigilanza-vaccini-covid-19"},{"key":"10.23749\/mdl.v112i6.12507_ref14","doi-asserted-by":"crossref","unstructured":"Cugno M, Consonni D, Lombardi A, et al. Increased risk of urticaria\/angioedema after BNT162b2 mRNA COVID-19 vaccine in health care workers taking ACE inhibitors. Vaccines. 2021;9(9):1-7. doi:10.3390\/vaccines9091011","DOI":"10.3390\/vaccines9091011"},{"key":"10.23749\/mdl.v112i6.12507_ref15","doi-asserted-by":"crossref","unstructured":"Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol. 2004;159(7):702-706. doi:10.1093\/aje\/kwh090","DOI":"10.1093\/aje\/kwh090"},{"key":"10.23749\/mdl.v112i6.12507_ref16","doi-asserted-by":"crossref","unstructured":"Kadali RAK, Janagama R, Peruru S, Malayala S V. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376-381. doi:10.1016\/j.ijid.2021.04.047","DOI":"10.1016\/j.ijid.2021.04.047"},{"key":"10.23749\/mdl.v112i6.12507_ref17","doi-asserted-by":"crossref","unstructured":"Gee J, Paige Marquez ;, Su J, et al. MMWR, First Month of COVID-19 Vaccine Safety Monitoring \u2014 United States, December 14, 2020\u2013January 13, 2021.; 2020. https:\/\/www.meddra.","DOI":"10.15585\/mmwr.mm7008e3"},{"key":"10.23749\/mdl.v112i6.12507_ref18","doi-asserted-by":"crossref","unstructured":"Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-949. doi:10.1016\/S1473-3099(21)00224-3","DOI":"10.1016\/S1473-3099(21)00224-3"},{"key":"10.23749\/mdl.v112i6.12507_ref19","doi-asserted-by":"crossref","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G, Didierlaurent AM, Da Silva FT. The how\u2019s and what\u2019s of vaccine reactogenicity. npj Vaccines. 2019;4(1). doi:10.1038\/s41541-019-0132-6","DOI":"10.1038\/s41541-019-0132-6"},{"key":"10.23749\/mdl.v112i6.12507_ref20","doi-asserted-by":"crossref","unstructured":"Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mrna-based covid-19 vaccines. JAMA - J Am Med Assoc. 2021;325(21):2201-2202. doi:10.1001\/jama.2021.5374","DOI":"10.1001\/jama.2021.5374"},{"key":"10.23749\/mdl.v112i6.12507_ref21","doi-asserted-by":"crossref","unstructured":"Ripabelli G, Tamburro M, Buccieri N, et al. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. J Community Health. 2021;(0123456789). doi:10.1007\/s10900-021-01039-3","DOI":"10.1007\/s10900-021-01039-3"},{"key":"10.23749\/mdl.v112i6.12507_ref22","doi-asserted-by":"crossref","unstructured":"d\u2019Arminio Monforte A, Tavelli A, Perrone PM, et al. Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. EClinicalMedicine. 2021;36. doi:10.1016\/j.eclinm.2021.100914","DOI":"10.1016\/j.eclinm.2021.100914"},{"key":"10.23749\/mdl.v112i6.12507_ref23","doi-asserted-by":"crossref","unstructured":"El Yousfi M, Mercier S, Breuill\u00e9 D, et al. The inflammatory response to vaccination is altered in the elderly. Mech Ageing Dev. 2005;126(8):874-881. doi:10.1016\/j.mad.2005.03.008","DOI":"10.1016\/j.mad.2005.03.008"},{"key":"10.23749\/mdl.v112i6.12507_ref24","doi-asserted-by":"crossref","unstructured":"Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-349. doi:10.1016\/S1473-3099(10)70049-9","DOI":"10.1016\/S1473-3099(10)70049-9"},{"key":"10.23749\/mdl.v112i6.12507_ref25","doi-asserted-by":"crossref","unstructured":"Trigunaite A, Dimo J, J\u00f8rgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015;294(2):87-94. doi:10.1016\/j.cellimm.2015.02.004","DOI":"10.1016\/j.cellimm.2015.02.004"},{"key":"10.23749\/mdl.v112i6.12507_ref26","doi-asserted-by":"crossref","unstructured":"Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294(2):63-69. doi:10.1016\/j.cellimm.2015.01.018","DOI":"10.1016\/j.cellimm.2015.01.018"},{"key":"10.23749\/mdl.v112i6.12507_ref27","doi-asserted-by":"crossref","unstructured":"Singer K, Lumeng CN. The initiation of metabolic inflammation in childhood obesity. J Clin Invest. 2017;127(1):65-73. doi:10.1172\/JCI88882","DOI":"10.1172\/JCI88882"},{"key":"10.23749\/mdl.v112i6.12507_ref28","doi-asserted-by":"crossref","unstructured":"Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2\/Pfizer vaccination. J Infect. 2021;83(3):381-412. doi:10.1016\/j.jinf.2021.05.035","DOI":"10.1016\/j.jinf.2021.05.035"},{"key":"10.23749\/mdl.v112i6.12507_ref29","doi-asserted-by":"crossref","unstructured":"Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057-1058. doi:10.1016\/S0140-6736(21)00501-8","DOI":"10.1016\/S0140-6736(21)00501-8"},{"key":"10.23749\/mdl.v112i6.12507_ref30","doi-asserted-by":"crossref","unstructured":"Wise J. Covid-19: People who have had infection might only need one dose of mRNA vaccine. BMJ. 2021;372:n308. doi:10.1136\/bmj.n308","DOI":"10.1136\/bmj.n308"}],"container-title":["La Medicina del Lavoro","La Medicina del Lavoro | Work, Environment and Health"],"original-title":[],"link":[{"URL":"https:\/\/www.mattioli1885journals.com\/index.php\/lamedicinadellavoro\/article\/download\/12507\/10356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mattioli1885journals.com\/index.php\/lamedicinadellavoro\/article\/download\/12507\/10370","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mattioli1885journals.com\/index.php\/lamedicinadellavoro\/article\/download\/12507\/10356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:19:34Z","timestamp":1741778374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mattioli1885journals.com\/index.php\/lamedicinadellavoro\/article\/view\/12507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":30,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.23749\/mdl.v112i6.12507","relation":{"has-manifestation":[{"id-type":"other","id":"4-807-12507-g10356","asserted-by":"subject"},{"id-type":"other","id":"4-807-12507-g10370","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"4-807","asserted-by":"subject"}],"is-cited-by":[{"id-type":"doi","id":"10.3389\/fimmu.2023.1078736","asserted-by":"object"}]},"ISSN":["2532-1080","0025-7818"],"issn-type":[{"value":"2532-1080","type":"electronic"},{"value":"0025-7818","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"8"}}